预约演示
Novartis punts Pliant-partnered NASH prospect amid pipeline prioritization pivot
2023-02-24
临床1期临床2期引进/卖出蛋白降解靶向嵌合体
Walking away from PLN-1474 continues Novartis’ retreat from nonalcoholic steatohepatitis.
Novartis is nixingPLN-1474coholic steNovartisitis (NASH) cannonalcoholic steatohepatitists therapeutic focus, walking away from a Pliant Therapeutics program it paid $50 million for back in 2019.
Novartis past 10 montnonalcoholic steatohepatitis (NASH)izational structure focused on five core therapeutic segments: cardiovascuPliant Therapeuticslid tumors, immunology and neuroscience. While the Swiss drugmaker may pursue other therapeutic areas opportunistically, most of its R&D dollars will go into its core areas. NASH, once the subject of a big push by Novartis, is no longer a neat fit for its focus.
Pliant has paid the priceNovartisartis’ pipeline rethink. Late Thursday, the biotech revealed Novartis has decided to terminate its agreement “as psolid tumorsew strategy focusing on a limited number of therapeutic areas.”NASHNovartis
Pliantreement covered PLN-1474Novartisl molecule selective inhibitor of integrin αvß1. NovartiNovartis50 million upfront, and made an investment in Pliant, to secure rights to the then-preclinical prospect and candidates against up to three additional integrin research targets. Last year, Novartis paid another $4 million to license compounds associated with an integrin research target.
Walking away from PLN-PLN-1474tinues Novartis’ retreat from NASH. The Big Pharma licensNovartis0, an FGF21 stimulator, to Boston Pharmaceuticals in Pliantas well as dropping its FXR agonist tropifexor from the pipeline last year. The phase 1 candidate integrins now the last Novartis NASH aNovartisnding. But, with Pliant saying Novartis plans to “divest clinicalintegrinsets,” that prospect could also be on the way out.
Novartis’ nixing oPLN-147474 comes weNovartisr CEO Vas NarasNASHn, M.D., said he was “streLLF580ng the pipeline” and told Boston Pharmaceuticalssee the company “exiting additionaFXR agonistFXRssets as tropifexortry to prune out non-core areas.” The pruning is intFIA586to allow NovartisNovartisall its “scientific firepower and ingenuity toNovartisilding out a deep set of piNASHne assets” in its five core areas, Narasimhan said.
Novartisxits the deaPLN-1474 received $79 million from Novartis but without pocketing most of the $416 million in milestones covered by the deal. The biotech has added PLN-1474 back into its wholly owned pipeline—describing it as phase 2 ready—and expects to post phaNovartisa on bexotegrast, its lead drug, in idiopathic pulmonary fibrosis and primary sclerosing cholangitis this year.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。